| Carla Motley, | |
|
1720 N Westgate Dr Ste D, Boise, ID 83704-7164 | |
| (208) 334-0917 | |
| (208) 334-0926 |
| Full Name | Carla Motley |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1720 N Westgate Dr Ste D, Boise, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619349545 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SLP-1264 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Carla Motley, 1720 Westgate Drive. Suite D, Boise, ID 83704 Ph: (208) 334-0917 | Carla Motley, 1720 N Westgate Dr Ste D, Boise, ID 83704-7164 Ph: (208) 334-0917 |
News Archive
Following a decade of steady declines, a new national study released today by The Partnership at Drugfree.org and MetLife Foundation indicates that teen drug and alcohol use is headed in the wrong direction, with marked increases in teen use of marijuana and Ecstasy over the past three years.
Phadia today announced that it has entered into an agreement to acquire 100 per cent of the shares in the Chinese marketing company WKL from the parent company MeiRui. The acquisition is made through AllergonAB, a wholly owned subsidiary of Phadia, and is subject to approval by Chinese authorities.
By looking at National Health Interview Survey data of more than 230,000 patients from 1999-2009, researchers were able to compare Medicaid with privately insured patients. More than 39 percent of those enrolled in Medicaid in the sample used the ER versus 17.7 percent of privately insured patients. Medicaid patients wer much more likely to have "specific barriers to timely primary care."
Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.
NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR or Stalevo, in patients with advanced Parkinson's disease.
› Verified 9 days ago
Jennifer Dahms, MS/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2995 N Cole Rd, Suite 130, Boise, ID 83704 Phone: 208-559-2348 Fax: 888-559-4660 | |
Lauren Rose Addison, M.S. SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 8620 W Emerald St Ste 100, Boise, ID 83704 Phone: 208-898-1368 | |
Kelli Shaw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3115 N Sycamore Dr, Boise, ID 83703 Phone: 208-401-6401 | |
Christy Baltazor, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Megan Patrick, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Emily Chapman, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8860 W Evening Star Ln, Boise, ID 83709 Phone: 814-873-9144 | |
Kimberly Degraw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 901 N Curtis Rd Ste 204, Boise, ID 83706 Phone: 208-367-8282 |